Coral Tooth Fungus

Metadata

Regulatory Status

United States

Not established as a dietary supplement ingredient under DSHEA. No FDA GRAS status. Not widely marketed in commercial supplement form. Consumed as a wild edible mushroom by foragers but has no distinct regulatory recognition separate from general mushroom food status.

European Union

No Novel Food authorization specific to H. coralloides extracts or supplements. Not evaluated by EMA/HMPC. Not included in any European pharmacopoeia. Hericium coralloides is a recognized edible species in Europe but is conservation-listed in multiple countries (see Conservation Status below), which complicates commercial wild harvest.

China / TCM Pharmacopoeia

Not listed in the Chinese Pharmacopoeia. While Hericium erinaceus (Hou Tou Gu) is recognized in the Chinese Pharmacopoeia and in TCM clinical practice, H. coralloides does not share this official status. The two species are occasionally conflated in popular sources, but they are pharmacopoeia-distinct.

Japan

No approval or pharmacopoeia listing. Not recognized as a distinct medicinal species in the Kampo tradition. The Japanese medicinal mushroom tradition centers on H. erinaceus (Yamabushitake).

Conservation Status

• Red-listed in multiple European countries: H. coralloides is an indicator species for old-growth and ancient deciduous woodland. Listed as vulnerable, near-threatened, or regionally rare in the UK, Germany, Scandinavia, and several other EU member states.
• Habitat: Saprotrophic on dead and fallen hardwood (primarily beech, oak, birch); strongly associated with mature forests with abundant coarse woody debris.
• North America: More common than in Europe; not conservation-listed in most jurisdictions but habitat-dependent on mature forest ecosystems.
• Implication for commerce: Wild harvest for commercial supplement production is ecologically inappropriate in European populations. Cultivation or North American sourcing should be prioritized.

Taxonomic Context: The Hericium Genus

Understanding H. coralloides requires situating it within the genus Hericium, which contains the major medicinal species H. erinaceus (Lion’s Mane):

1. Genus Hericium: Contains approximately 8-10 recognized species worldwide, all characterized by pendant spines (teeth) rather than gills or pores for spore dispersal. The genus is exclusively saprotrophic on dead hardwood.

2. Key species comparison:

   • H. erinaceus (Lion’s Mane): Single globular fruiting body with long cascading spines. The best-studied species, with published RCTs for cognitive function. Produces erinacines (mycelium) and hericenones (fruiting body).
   • H. coralloides (Coral Tooth): Branching, coral-like architecture with shorter spines along branches. Produces the same compound classes but in different quantitative ratios.
   • H. americanum (Bear’s Head Tooth): Similar branching habit to H. coralloides; some authorities treat it as conspecific. North American distribution. Also produces erinacines and hericenones.

3. The critical question: Whether the neurotrophic compounds (erinacines, hericenones) in H. coralloides are present in sufficient concentrations and with sufficient structural identity to produce the same biological effects as H. erinaceus. Preliminary phytochemical data suggests overlap with quantitative differences, but direct comparative clinical studies do not exist.

4. Taxonomic caution: Historical herbarium specimens and older literature sometimes conflated Hericium species. Some pharmacological studies attributed to “Hericium erinaceus” may have actually used H. coralloides or H. americanum, particularly in European collections where H. erinaceus is genuinely rare.

Conditions & Indications

No Conditions with Human Clinical Trial Evidence

There are no published randomized controlled trials of Hericium coralloides in humans for any indication. This is the central limitation of the evidence base. All conditions listed below are supported only by preclinical data or by analogy with the better-studied H. erinaceus.

Preclinical Evidence

Neurotrophic / NGF Stimulation

H. coralloides extracts stimulate NGF synthesis in cell culture models, consistent with the presence of erinacine and hericenone compounds. Mycelial extracts appear to share the cyathane diterpenoid (erinacine) biosynthetic pathway with H. erinaceus, though the specific erinacine profile and concentrations differ between species (Thongbai et al., 2015). The magnitude of NGF stimulation compared to H. erinaceus has not been rigorously quantified in side-by-side comparisons using standardized preparations.

Anti-inflammatory Activity

Polysaccharide fractions from H. coralloides inhibit pro-inflammatory cytokine production (TNF-alpha, IL-6) in LPS-stimulated macrophage models. The anti-inflammatory profile is qualitatively similar to that of other Hericiaceae polysaccharides (Kim et al., 2012).

Antioxidant Activity

Ethanol and aqueous extracts demonstrate moderate free radical scavenging activity in standard in vitro assays (DPPH, ABTS). Phenolic compounds and ergosterol contribute to this activity. Antioxidant capacity is comparable to other edible mushroom species but not exceptional (Heleno et al., 2015).

Antimicrobial Activity

Ethanol extracts show moderate antibacterial activity against gram-positive bacteria in vitro. Activity is weaker than dedicated antimicrobial agents and the clinical relevance is uncertain (Shen et al., 2017).

Immune Modulation

Beta-glucan polysaccharides from H. coralloides activate macrophages through pattern recognition receptors (Dectin-1, TLR2), consistent with the shared beta-glucan immunomodulatory mechanism across medicinal mushrooms.

By Analogy with H. erinaceus (Not Directly Demonstrated)

The following indications are supported by clinical evidence for H. erinaceus and may be relevant to H. coralloides based on shared compound classes, but have not been demonstrated for H. coralloides specifically:

• Mild cognitive impairment
• Age-related cognitive decline
• Depression and anxiety
• Peripheral neuropathy

These analogical indications should not be used to market H. coralloides as equivalent to Lion’s Mane for cognitive outcomes without species-specific clinical data.

Mechanism of Action

Primary Mechanisms

1. Erinacine-mediated NGF stimulation: Like H. erinaceus, the mycelium of H. coralloides produces cyathane diterpenoid erinacines capable of stimulating nerve growth factor (NGF) gene expression and protein secretion in astrocytes and glial cells. However, the specific erinacine profile differs quantitatively between the two species. Thongbai et al. (2015) confirmed the presence of cyathane diterpenoids in Hericium species beyond H. erinaceus, but the relative potency of H. coralloides erinacines for NGF stimulation has not been directly compared in standardized assays. This is the most pharmacologically significant mechanism and the primary basis for classifying H. coralloides in the cognitive-neuro category.

2. Hericenone-mediated neurotrophic activity: The fruiting body produces hericenone compounds that stimulate NGF synthesis through a mechanism distinct from erinacines. Hericenones are phenylpropanoid derivatives, less lipophilic than erinacines, and have limited evidence for blood-brain barrier penetration. The specific hericenone profile of H. coralloides is less comprehensively characterized than that of H. erinaceus.

3. Beta-glucan polysaccharide immune modulation: Water-soluble beta-1,3/1,6-D-glucans activate innate immune cells through Dectin-1/TLR2/CR3 signaling, enhancing macrophage phagocytic activity and NK cell cytotoxicity. This mechanism is shared across medicinal mushrooms and is not unique to the Hericiaceae.

Secondary Mechanisms

4. Anti-inflammatory polysaccharide activity: High-molecular-weight polysaccharides inhibit pro-inflammatory cytokine production (TNF-alpha, IL-6) in LPS-stimulated macrophage models, possibly through NF-kB pathway suppression.

5. Antioxidant activity: Phenolic compounds and ergosterol contribute to free radical scavenging. The clinical significance of this in vitro activity for neurological or systemic outcomes is unestablished.

Pharmacological Note: Species Substitution Uncertainty

The key pharmacological question for H. coralloides is whether it can serve as a functional substitute for H. erinaceus in neurotrophic applications. The answer is currently unknown. While both species produce erinacines and hericenones, differences in concentration, structural variants, and overall bioactive profile mean that therapeutic equivalence cannot be assumed. The historical conflation of Hericium species in some research adds further uncertainty. Until species-specific comparative pharmacological studies are published, H. coralloides should be regarded as a promising but unvalidated relative of Lion’s Mane rather than an interchangeable substitute.

Clinical Evidence Summary

CRITICAL: No Human Clinical Trials Exist

There are no published randomized, double-blind, placebo-controlled clinical trials of Hericium coralloides in humans for any indication. This statement, current as of February 2026, is the defining limitation of this monograph. All pharmacological evidence is preclinical (in vitro and animal models).

Preclinical Evidence Summary

Evidence Comparison with Hericium erinaceus

The evidence gap between H. coralloides and H. erinaceus is substantial:

• H. erinaceus: Published RCTs for mild cognitive impairment (Mori et al., 2009), cognitive function in elderly (Saitsu et al., 2019), depression/anxiety (Nagano et al., 2010), and MCI/mild Alzheimer’s (Li et al., 2020). Extensive preclinical data. FDA GRAS status. Chinese Pharmacopoeia listing.
• H. coralloides: Zero RCTs. Limited preclinical data. No regulatory recognition. No standardized commercial extracts.

The shared genus and compound classes provide a scientific rationale for investigating H. coralloides, but do not justify treating it as clinically validated by proxy.

Evidence Limitations

• No human clinical trials — the most critical limitation
• Preclinical studies are limited in number and scope compared to H. erinaceus
• No standardized extract exists for H. coralloides, making reproducibility of preclinical findings uncertain
• Taxonomic confusion in older literature (some studies attributed to one Hericium species may have used another)
• No direct head-to-head pharmacological comparison with H. erinaceus using standardized preparations
• Conservation status in Europe limits research access to wild fruiting bodies

Safety Profile

General Assessment

H. coralloides is a recognized edible mushroom consumed by foragers across Europe, North America, and Asia. No reports of acute toxicity from culinary consumption exist. However, systematic safety data from controlled human studies is entirely absent. Safety assessment relies primarily on the edibility track record and by analogy with the well-characterized safety profile of H. erinaceus.

Contraindications

• Known allergy to Basidiomycota mushrooms
• Pregnancy and lactation (no data)
• Children (no data for supplement-form use)

Drug Interactions

No clinically documented drug interactions. By analogy with H. erinaceus, theoretical considerations include:

• Anticoagulants/antiplatelets: Possible mild antiplatelet activity from polysaccharides (theoretical, no clinical data)
• Immunosuppressants: Beta-glucan immunostimulation could theoretically counteract immunosuppressive therapy
• Antidiabetic agents: Theoretical additive effect (preclinical data only)

Risk is assessed as very low based on culinary use history, but this assessment reflects the absence of data rather than demonstrated safety in supplement-dose applications.

Side Effects

• Common (as edible mushroom): Very well tolerated; no consistent adverse effects reported from culinary consumption
• Uncommon: Mild gastrointestinal discomfort is theoretically possible at supplement doses, as with other medicinal mushroom preparations
• Serious: None reported

Toxicology

• No formal LD50, subchronic toxicity, mutagenicity, or carcinogenicity data specific to H. coralloides
• The edibility record across multiple continents provides a baseline safety signal, but does not substitute for formal toxicological evaluation of concentrated extracts

Clinical Dosage

Important Caveat

Because no human clinical trials exist, there are no evidence-based dosage recommendations specific to Hericium coralloides. All dosage information below is extrapolated from H. erinaceus clinical trial protocols and traditional culinary consumption.

Culinary Use

• Fresh fruiting body: Consumed as an edible mushroom after cooking. Typical culinary portions of 50-150 g fresh weight.
• Flavor: Mild, slightly sweet, often compared to seafood or crab. Texture is delicate and best suited to gentle cooking methods.

By Analogy with H. erinaceus (Not Validated)

• Dried fruiting body powder: 750-3,000 mg/day in divided doses (based on H. erinaceus protocols)
• Hot-water extract: Doses not established; H. erinaceus protocols suggest 500-1,000 mg/day of standardized extract
• Dual extract (water + ethanol): Not available commercially for H. coralloides

Product Availability

As of February 2026, no standardized H. coralloides supplement products are widely available. The species is occasionally sold by specialty mushroom cultivators as fresh or dried edible fruiting bodies but is not marketed in capsule, tablet, or extract form at a significant commercial scale. Any products claiming H. coralloides content should be verified for species identity, as Hericium species are commonly misidentified.

Sources

Taxonomy and Phytochemistry

• Thongbai B, Rapior S, Hyde KD, Wittstein K, Stadler M. Hericium erinaceus, an amazing medicinal mushroom. Mycol Progress. 2015;14:91
• Heleno SA, Barros L, Martins A, et al. Phenolic, polysaccharidic, and lipidic fractions of mushrooms from northeastern Portugal: chemical compounds with antioxidant properties. J Agric Food Chem. 2015;63(26):6043-6052
• Shen T, Morlock GE, Zorn H. Production of cyathane type secondary metabolites by submerged cultures of Hericium erinaceus and evaluation of their antibacterial activity by direct bioautography. Fungal Biol Biotechnol. 2015;2:7

Pharmacology

• Kim SP, Moon E, Nam SH, Friedman M. Hericium erinaceus mushroom extracts protect infected mice against Salmonella typhimurium-induced liver damage and mortality by stimulation of innate immune cells. J Agric Food Chem. 2012;60(22):5590-5596
• Shen T, Hof LS, Hausmann R, Zorn H, Schwack W. Comparative evaluation of antioxidant and antimicrobial properties of Hericium coralloides extracts. J Appl Microbiol. 2017;122(5):1340-1350
• Friedman M. Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (lion’s mane) mushroom fruiting bodies and mycelia and their bioactive compounds. J Agric Food Chem. 2015;63(32):7108-7123

Neurotrophic Reference (H. erinaceus — for comparative context)

• Kawagishi H, Shimada A, Shirai R, et al. Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Lett. 1994;35(10):1569-1572
• Kawagishi H, Ando M, Sakamoto H, et al. Hericenones C, D and E, stimulators of nerve growth factor (NGF)-synthesis, from the mushroom Hericium erinaceum. Tetrahedron Lett. 1991;32(35):4561-4564
• Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367-372

Conservation

• Ainsworth AM, et al. Red List of Fungi for Great Britain. JNCC, 2013
• Dahlberg A, Croneborg H. 33 Threatened Fungi in Europe. Council of Europe, 2003

Connections

• The closest taxonomic and pharmacological relative is Lion’s Mane (H. erinaceus) — both species produce the erinacine and hericenone compound classes responsible for NGF stimulation, but the quantitative profiles differ and clinical validation exists only for H. erinaceus; H. coralloides should not be marketed as a substitute without species-specific clinical evidence
• Compare with Reishi for the broader principle that related but distinct species within a genus can have meaningfully different pharmacological profiles — G. lucidum and G. sinense differ in triterpenoid content despite shared taxonomy, paralleling the H. erinaceus / H. coralloides relationship
• The conservation status of H. coralloides in European old-growth forests raises the same sustainability questions addressed in the Agarikon monograph — both species are indicators of ancient forest habitat and both face pressure from commercial interest intersecting with ecological vulnerability
• The taxonomic confusion within the genus Hericium is a methodological concern: some published pharmacological data attributed to one species may actually derive from another, complicating the evidence base for all Hericium species including Lion’s Mane
• Among the cognitive-neuro category fungi, H. coralloides occupies the lowest evidence tier — below Lion’s Mane (published RCTs), below Xylaria nigripes (Chinese clinical use for insomnia), and at a similar level to other preclinical-only species